{
    "clinical_study": {
        "@rank": "38358", 
        "arm_group": [
            {
                "arm_group_label": "Home Care", 
                "arm_group_type": "Experimental", 
                "description": "This is the arm for patients who receive their transplant care in their homes."
            }, 
            {
                "arm_group_label": "Hospital Care", 
                "arm_group_type": "No Intervention", 
                "description": "Standard of care for stem cell transplant recipients where the aftercare is done in hospital."
            }, 
            {
                "arm_group_label": "Clinic Care", 
                "arm_group_type": "No Intervention", 
                "description": "Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary goal with this study is to document whether patients can maintain their normal\n      bowel microbiota by staying at home compared to being in the hospital. In addition, the\n      investigators would predict that the quality of life will be higher for those patients\n      treated at the medical home compared to those that stay at the hospital. The investigators\n      also predict that the costs associated with this approach will be significantly lower\n      compared to hospitalized patients. Finally, the investigators propose that the treatment\n      related morbidities and mortality will not be different between the two groups."
        }, 
        "brief_title": "A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Hematologic Malignancies", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects enrolled in the medical home arm and those serving as concurrent controls will have\n      the following studies:\n\n        1. Stool collection for analysis at time 0 (prior to preparatory regimen) and then weekly\n           for the first four weeks, at day 60 and 100.\n\n        2. The PG-SGA, FACT-BMT and other patient-reported symptom instruments will be collected\n           weekly for the first 4 weeks, at day 60, 100 and patients will be required to complete\n           a daily food diary.\n\n        3. Other assessments for toxicities or GVHD will proceed as per current standard of care,\n           for a total blood draw amount of 100 mls from home care subjects and concurrent\n           controls."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Scheduled to undergo a hematopoietic stem cell transplant for any cancer or\n             non-cancer illness from any autologous, related or unrelated donor source including\n             bone marrow, peripheral blood progenitor cell, or umbilical cord blood\n\n          2. Age 18-80 years of age\n\n          3. Karnofsky Performance Scale (KPS) > 80\n\n          4. A home that is deemed, upon inspection, in suitable condition to serve as a medical\n             home, within a 90-minute driving distance of Duke (home care group only)\n\n        Exclusion Criteria:\n\n          1. Lack of a caregiver\n\n          2. Pregnant women (It is standard of care to assess for pregnancy for all females of\n             child-bearing potential with a serum beta human chorionic gonadotropin (HCG) test\n             within 7 days of starting the preparative regimen prior to transplant.  No additional\n             research pregnancy testing will occur.)\n\n          3. Patients with a documented active infection prior to starting their preparative\n             regimen.  This includes grade 3 or higher viral, bacterial, or fungal infection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725022", 
            "org_study_id": "Pro00032263"
        }, 
        "intervention": {
            "arm_group_label": "Home Care", 
            "description": "This is the interventional arm where patients receive the transplant care in their homes.", 
            "intervention_name": "Home Care", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stem cell transplant", 
            "bowel microbiota", 
            "home care"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "krista.rowe@duke.edu", 
                "last_name": "Krista Rowe, MSN, AOCNS", 
                "phone": "919-684-7115"
            }, 
            "contact_backup": {
                "email": "mcdon011@mc.duke.edu", 
                "last_name": "Carolyn McDonald, RN, ONS", 
                "phone": "919-613-5042"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Nelson Chao, MD, MBA", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care", 
        "overall_contact": {
            "email": "krista.rowe@duke.edu", 
            "last_name": "Krista Rowe, MSN, AOCNS", 
            "phone": "(919) 684-7115"
        }, 
        "overall_contact_backup": {
            "email": "martha.lassiter@duke.edu", 
            "last_name": "Martha Lassiter, MSN OCN", 
            "phone": "(919) 668-6239"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Nelson Chao, MD, MBA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The bowel microbiota before and during the first 100 days.", 
            "measure": "Bowel Microbiota", 
            "safety_issue": "Yes", 
            "time_frame": "100 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725022"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The assessment tool to capture overall nutritional status will be the Patient Generated Subjective Global Assessment (PG-SGA) which has been validated in other cancer patients.", 
                "measure": "Nutritional status using the PG-SGA assessment tool", 
                "safety_issue": "Yes", 
                "time_frame": "100 days"
            }, 
            {
                "description": "All incidences of Grade II-IV GVHD will be quantified.", 
                "measure": "Incidence of acute Graft Versus Host Disease (GVHD)", 
                "safety_issue": "Yes", 
                "time_frame": "100 days"
            }, 
            {
                "description": "Both treatment related morbidities and mortalities will be quantified.", 
                "measure": "Treatment related morbidities and mortalities", 
                "safety_issue": "Yes", 
                "time_frame": "100 Days"
            }, 
            {
                "description": "The QOL assessment will utilize the FACT-BMT (Functional Assessment of Cancer Therapy Bone Marrow Transplant) assessment tool as well as other patient-reported symptom instruments to capture the patient reported experience.", 
                "measure": "Quality Of Life Assessment (QOL)", 
                "safety_issue": "No", 
                "time_frame": "100 Days"
            }, 
            {
                "description": "The mean, median and range of costs will be compared (treatment costs within the hospital versus the same treatment costs at home).", 
                "measure": "Costs of care", 
                "safety_issue": "No", 
                "time_frame": "100 Days"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}